This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.β
Welireg (belzutifan)
General Description:
Welireg (belzutifan) is an oral targeted therapy used in combination with other medicines to treat adults with cancers associated with von Hippel-Lindau (VHL) disease. It works by inhibiting HIF-2Ξ±, a protein that contributes to tumor growth, helping to slow disease progression and improve patient outcomes.
Welireg is administered orally as tablets, with dosage and treatment schedules determined by a qualified healthcare professional based on individual patient needs.
Getting Welireg (belzutifan) in India
Welireg is approved by major international regulatory agencies, including the FDA (U.S.) and EMA (Europe). While it may not yet be commercially available in India, patients can access it legally through a Named Patient Program (NPP) under the supervision of a licensed physician.
MitoGENE assists Indian patients in obtaining Welireg safely, coordinating all regulatory approvals, import permits, and logistics for a secure and compliant process.
Disease Indication:
β’ Kidney Cancer / VHL-associated Cancers
Manufacturer:
Merck
Usage:
Oral Tablets
Medicine Approved By:
β’ Food and Drug Administration (FDA)
β’ European Medicines Agency (EMA)
Available Dosage Form & Package:
β’ 40 mg tablets, 90 tablets per pack
Shipping:
Room Temperature Shipping
Welireg is shipped under controlled room temperature conditions (15β25Β°C) to maintain stability and effectiveness. Standard shipping procedures ensure the medication remains safe and uncompromised during transit.
How to Access Welireg (belzutifan) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Welireg (belzutifan) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Hereβs how the process works:
